Mining high‐throughput screens for cancer drug targets—lessons from yeast chemical‐genomic profiling and synthetic lethality
暂无分享,去创建一个
[1] J. C. Hinshaw,et al. Discovering Modes of Action for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes , 2004, Cell.
[2] Alan Ashworth,et al. Searching for synthetic lethality in cancer. , 2011, Current opinion in genetics & development.
[3] M. Roberge,et al. Yeast as a tool to uncover the cellular targets of drugs , 2006, Biotechnology journal.
[4] Ted Powers,et al. TOR Complex 1 Includes a Novel Component, Tco89p (YPL180w), and Cooperates with Ssd1p to Maintain Cellular Integrity in Saccharomyces cerevisiae* , 2004, Journal of Biological Chemistry.
[5] Damian Szklarczyk,et al. STITCH 2: an interaction network database for small molecules and proteins , 2009, Nucleic Acids Res..
[6] H. Bussey,et al. Exploring genetic interactions and networks with yeast , 2007, Nature Reviews Genetics.
[7] Grant W. Brown,et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways , 2004, Nature Biotechnology.
[8] Ben Lehner,et al. Evolutionary plasticity of genetic interaction networks , 2008, Nature Genetics.
[9] Daphne Koller,et al. Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action , 2010, Genome Biology.
[10] Elizabeth A. Winzeler,et al. Genomic profiling of drug sensitivities via induced haploinsufficiency , 1999, Nature Genetics.
[11] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[12] D. Silver,et al. Synthetic lethality--a new direction in cancer-drug development. , 2009, The New England journal of medicine.
[13] O. Kallioniemi,et al. High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth , 2009, Clinical Cancer Research.
[14] B. Zupan,et al. Inference of the molecular mechanism of action from genetic interaction and gene expression data. , 2010, Omics : a journal of integrative biology.
[15] Corey Nislow,et al. A survey of yeast genomic assays for drug and target discovery. , 2010, Pharmacology & therapeutics.
[16] Robert P. St.Onge,et al. Defining genetic interaction , 2008, Proceedings of the National Academy of Sciences.
[17] Yudong D. He,et al. Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.
[18] Michael Peyton,et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.
[19] Gary D Bader,et al. The Genetic Landscape of a Cell , 2010, Science.
[20] D. Pe’er,et al. Principles and Strategies for Developing Network Models in Cancer , 2011, Cell.
[21] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[22] Ricard V. Solé,et al. Human synthetic lethal inference as potential anti-cancer target gene detection , 2009, BMC Systems Biology.
[23] Dongsup Kim,et al. Inference of Protein Complex Activities from Chemical-Genetic Profile and Its Applications: Predicting Drug-Target Pathways , 2008, PLoS Comput. Biol..
[24] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[25] Ronald W. Davis,et al. Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.
[26] Michael Costanzo,et al. Charting the genetic interaction map of a cell. , 2011, Current opinion in biotechnology.
[27] Michael I. Jordan,et al. A latent variable model for chemogenomic profiling , 2005, Bioinform..
[28] Ronald W. Davis,et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.
[29] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[30] Nir Hacohen,et al. Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.
[31] L. Hartwell,et al. Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.
[32] Michael I. Jordan,et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[33] P. Hieter,et al. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing , 2009, Proceedings of the National Academy of Sciences.
[34] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[35] B. Roberts,et al. Saccharomyces cerevisiae PAC2 functions with CIN1, 2 and 4 in a pathway leading to normal microtubule stability. , 1997, Genetics.
[36] Nevan J Krogan,et al. Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action , 2010, Molecular systems biology.
[37] Tero Aittokallio,et al. Quantitative maps of genetic interactions in yeast - Comparative evaluation and integrative analysis , 2011, BMC Systems Biology.
[38] Corey Nislow,et al. Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.
[39] Robert P. St.Onge,et al. The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes , 2008, Science.
[40] S. Nijman. Synthetic lethality: General principles, utility and detection using genetic screens in human cells , 2011, FEBS letters.
[41] Jeff Piotrowski,et al. Combining functional genomics and chemical biology to identify targets of bioactive compounds. , 2011, Current opinion in chemical biology.
[42] A. Murray,et al. The spindle checkpoint of budding yeast depends on a tight complex between the Mad1 and Mad2 proteins. , 1999, Molecular biology of the cell.
[43] Robert P. St.Onge,et al. Genome-Wide Requirements for Resistance to Functionally Distinct DNA-Damaging Agents , 2005, PLoS genetics.
[44] N. Hacohen,et al. Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.
[45] William A Weiss,et al. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.
[46] Jae K. Lee,et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. , 2011, Neoplasia.